In a recent development, the Office of Prescription Drug Promotion (OPDP) of the Food and Drug Administration (FDA) has issued another Untitled Letter. This has led to speculations within the pharmaceutical and legal fraternity regarding the intent and future direction of OPDP’s enforcement efforts.
This letter marks the second instance within a span of two months that the OPDP has delivered an Untitled Letter. Interestingly, this was also followed by a Warning Letter issued in quick succession. The speed and frequency of these letters have ignited conversations and raised questions about whether we might be witnessing a new trend in OPDP’s enforcement policy.
The situation evokes the words of the 1973 song, “Nostradamus,” where singer-songwriter Al Stewart sang, “I am the eyes of Nostradamus, all your ways are known to me.” In the current context, the legal and pharmaceutical industry is left wondering about Al Stewart’s take on this development.
Given the recent spate of actions by the OPDP, the question that needs immediate traction is – Does this hint towards a more rigorous enforcement regime? While it’s early days to decisively interpret these actions, a close monitoring of OPDP’s further actions is necessitated to validate any such inferences.
It’s also imperative to note that consistency in the issuance of a Warning Letter and Untitled Letters, within a short interval, could signal an increased enforcement tempo or change in approach by the OPDP.
Although these observations are speculative, they underscore the criticality for pharmaceutical companies and their legal counsels to stay vigilant about regulatory correspondences and their respective implications.
More clarity on this development can be obtained from the detailed article shared by Arnall Golden Gregory LLP, available here.